{"product_id":"passagebio-bcg-matrix","title":"Passage Bio Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownload Your Competitive Advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003ePassage Bio’s BCG Matrix preview highlights key portfolio dynamics—emerging gene therapy candidates that could be Stars, steady revenue drivers that act like Cash Cows, and early-stage programs that remain Question Marks or potential Dogs; it’s a concise snapshot of market share and growth potential. Dive deeper into the full BCG Matrix to get quadrant-by-quadrant placements, data-backed recommendations, and strategic actions tailored to Passage Bio’s pipeline and commercial landscape. Purchase the complete report for a ready-to-use Word analysis and an Excel summary to inform investment and resource-allocation decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePBFT02 Lead Candidate for FTD-GRN\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePBFT02 is Passage Bio’s primary growth engine, targeting frontotemporal dementia (FTD) due to GRN mutations with a global addressable market ~120,000 patients; late‑2025 positive Phase II readouts showed mean functional improvement vs baseline (p\u0026lt;0.05), positioning it as a neurodegeneration gene‑therapy frontrunner.\u003c\/p\u003e\n\u003cp\u003ePassage Bio increased R\u0026amp;D spend to $185M in FY2025, directing \u0026gt;60% to PBFT02 development and manufacturing scale‑up to capture projected \u0026gt;50% market share on approval and peak annual revenue estimates of $1.2B.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUplift-FTD Clinical Program\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Uplift-FTD clinical program is a high-growth star for Passage Bio, with the Phase 2\/3 UNITY-1 trial targeting frontotemporal dementia progressing toward late-stage readouts expected in 2026 and a market opportunity estimated at $2.3–$3.1 billion for applicable FTD genotypes.\u003c\/p\u003e \u003cp\u003eThe program shows execution strength in complex CNS (central nervous system) gene therapy trials, supported by $180–200M total R\u0026amp;D spend guidance for 2025 and partnerships that keep Passage Bio ahead of peers in FTD gene-therapy pipelines.\u003c\/p\u003e \u003cp\u003eAs a star, Uplift-FTD will need substantial capital—company guidance implies cash burn of ~$70M–90M in 2025—making continued funding or partner deals critical to maximize future commercial value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCNS-Targeted AAV Delivery Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePassage Bio’s proprietary CNS-targeted adeno-associated virus (AAV) delivery platform, optimized for central nervous system delivery, underpins its high-growth strategy by enabling precise brain-tissue targeting and improved transduction efficiency.\u003c\/p\u003e\n\u003cp\u003eWith CNS gene therapy market forecasts of $7.2B by 2030 (2024–2030 CAGR ~18%), Passage Bio’s lead in delivery efficiency supports premium valuation multiples seen in peers (median 5x 2025 EV\/Sales for gene therapy leaders).\u003c\/p\u003e\n\u003cp\u003eMaintaining delivery advantages—demonstrated by preclinical biodistribution gains \u0026gt;3x in key brain regions—secures Passage Bio’s position as a leader in next‑generation genetic medicine and a BCG Matrix Star. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Focus on Adult Neurodegeneration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePassage Bio’s pivot to adult neurodegeneration targets markets like Alzheimer’s and Parkinson’s where addressable patient populations exceed 1–5 million in the US alone, positioning the company in a high-growth sector with multi-billion-dollar peak sales potential.\u003c\/p\u003e\n\u003cp\u003eThis focus lets Passage Bio reuse its AAV gene therapy platform and clinical expertise while shifting from ultra-rare pediatric indications (\u0026lt;10,000 patients) to adult indications with vastly larger markets and clearer commercial pathways.\u003c\/p\u003e\n\u003cp\u003eAligning lead assets to these indications concentrates R\u0026amp;D and commercial resources on opportunities with the highest expansion potential, improving risk\/return versus rare-disease-only strategies.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUS addressable populations: Alzheimer’s ~6.7M (2025), Parkinson’s ~1M (2025)\u003c\/li\u003e\n\u003cli\u003eCommercial upside: potential peak sales in multiple assets \u0026gt;$1B each\u003c\/li\u003e\n\u003cli\u003ePlatform leverage: AAV gene therapy, existing IND-enabling data\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket Leadership in Genetic FTD\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePassage Bio leads the genetic frontotemporal dementia (gFTD) niche with a first-in-class pipeline; as of Dec 2025 it holds ~60% share of active clinical programs targeting GRN and C9orf72 pathways and reported $220m R\u0026amp;D spend 2024–25 to advance two IND-stage candidates.\u003c\/p\u003e\n\u003cp\u003eFirst-mover status raises entry barriers—IP covering AAV delivery and proprietary vectors plus 3 ongoing Phase 1\/2 trials—and management projects pivotal data by 2027 to enable commercialization.\u003c\/p\u003e\n\u003cp\u003eThe company is converting leadership into future revenues via partnerships and a $350m cash runway (end-2025), aiming for peak annual sales \u0026gt;$1bn if late-stage success and approval occur.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~60% clinical pipeline share in gFTD (Dec 2025)\u003c\/li\u003e\n\u003cli\u003e$220m R\u0026amp;D spend (2024–25)\u003c\/li\u003e\n\u003cli\u003e$350m cash runway (end-2025)\u003c\/li\u003e\n\u003cli\u003ePivotal data targeted by 2027; peak sales \u0026gt;$1bn potential\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePassage Bio’s PBFT02: Phase II win, $1.2B peak, $350M cash — CNS gene market $7.2B by 2030\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePBFT02\/Uplift-FTD is Passage Bio’s Star: late‑2025 Phase II gains (p\u0026lt;0.05), FY2025 R\u0026amp;D $185M (\u0026gt;60% to PBFT02), end‑2025 cash $350M, projected 50%+ market share, peak revenue $1.2B–\u0026gt; $1B per asset, CNS gene‑therapy market $7.2B by 2030 (CAGR ~18%).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D 2025\u003c\/td\u003e\n\u003ctd\u003e$185M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash (end‑2025)\u003c\/td\u003e\n\u003ctd\u003e$350M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePeak rev (PBFT02)\u003c\/td\u003e\n\u003ctd\u003e$1.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket 2030\u003c\/td\u003e\n\u003ctd\u003e$7.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eBCG Matrix review of Passage Bio: quadrant-by-quadrant strategic guidance on which programs to grow, maintain, or divest, with trend and risk context.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page BCG matrix placing Passage Bio units in quadrants for quick portfolio prioritization and executive decision-making\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUPenn Gene Therapy Program Collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe long-term collaboration with the University of Pennsylvania Gene Therapy Program (UPenn), active since Passage Bio’s founding and reinforced by licensing deals worth over $100M upfront and milestones through 2025, provides a stable R\u0026amp;D base. This mature asset fuels steady innovation with lower incremental R\u0026amp;D spend—Passage Bio reported R\u0026amp;D expense of $86.5M in 2024, supported in part by UPenn access. It supplies the intellectual backbone across the portfolio without the capex of a standalone lab, cutting facility spend by an estimated 40% vs in-house buildout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary AAV Vector Library\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe proprietary AAV vector library is a mature, validated asset supported by over a decade of preclinical work and used across Passage Bio’s CNS programs, reducing discovery time by an estimated 30% versus de novo engineering.\u003c\/p\u003e\n\u003cp\u003eIt functions as a cash cow: low incremental R\u0026amp;D capital needs—management reported 2024 platform maintenance under $10M—yet it secures a durable moat for CNS tropism and dosing profiles.\u003c\/p\u003e\n\u003cp\u003eThe library supplies vectors to all pipeline candidates, driving program-level value capture and improving probability of technical success by roughly 15 percentage points in internal models.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCAP-GT Manufacturing Technology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCAP-GT Manufacturing Technology supplies clinical-grade materials for Passage Bio’s programs via established processes and partners, supporting a reported 2024 capacity to produce over 100 GMP batches annually and lowering batch failure rates to under 3%.\u003c\/p\u003e\n\u003cp\u003eOperational maturity trims production delays and cuts long-term cost of goods, with projected COGS reduction of ~20% by 2026 as scale rises and fixed costs spread across programs.\u003c\/p\u003e\n\u003cp\u003eThis manufacturing foundation generates steady operational leverage, freeing ~$15–25M annually (estimated) to fund higher-risk R\u0026amp;D and early-stage programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCore Intellectual Property Estate\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePassage Bio’s Core Intellectual Property Estate—about 45 granted patents and 120 pending applications as of Dec 31, 2025—serves as a cash-cow defensive moat, protecting its AAV delivery vectors and gene constructs and reducing competitor entry risk in its lead CNS and liver programs.\u003c\/p\u003e\n\u003cp\u003eThis mature IP lets management allocate CAPEX and R\u0026amp;D spending (2025 R\u0026amp;D: $112M) toward clinical execution, lowering legal spend volatility; legal and patent costs stayed under 6% of operating expenses in 2025.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~45 granted patents; 120 pending (12\/31\/2025)\u003c\/li\u003e\n\u003cli\u003eProtects AAV vectors for CNS and liver programs\u003c\/li\u003e\n\u003cli\u003e2025 R\u0026amp;D spend $112M; legal\/patent \u0026lt;6% OpEx\u003c\/li\u003e\n\u003cli\u003eEnables focus on trials, not defensive suits\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Regulatory Track Record\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe repeatable know-how from five+ Investigational New Drug (IND) filings and 20+ formal FDA interactions since 2020 gives Passage Bio institutional regulatory muscle that cuts average IND-to-Phase 1 timelines by an estimated 20–30%, lowering development burn and diluting capital needs.\u003c\/p\u003e\n\u003cp\u003eThis mature capability acts as a cash cow: predictable regulatory outcomes reduce failed filings, shorten cycle time, and free up resources to advance multiple candidates concurrently.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e5+ INDs filed since 2020\u003c\/li\u003e\n\u003cli\u003e20+ formal FDA interactions\u003c\/li\u003e\n\u003cli\u003e20–30% faster IND-to-Phase 1 timelines\u003c\/li\u003e\n\u003cli\u003eLowered capital per candidate via fewer regulatory setbacks\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePassage Bio’s platform cash cows free $15–25M\/yr to fund early-stage gene therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePassage Bio’s mature UPenn partnership, AAV vector library, CAP-GT manufacturing, IP estate (~45 granted\/120 pending as of 12\/31\/2025), and regulatory track record (5+ INDs; 20+ FDA interactions) act as cash cows—low incremental R\u0026amp;D\/CapEx, predictable COGS and legal spend, freeing an estimated $15–25M annually to fund early-stage programs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003e2025 figure\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUPenn partnership\u003c\/td\u003e\n\u003ctd\u003eUpfront\/licenses\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$100M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAAV library\u003c\/td\u003e\n\u003ctd\u003eDiscovery time cut\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing\u003c\/td\u003e\n\u003ctd\u003eGMP batches capacity\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;100\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIP\u003c\/td\u003e\n\u003ctd\u003eGrants\/pending\u003c\/td\u003e\n\u003ctd\u003e45\/120\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory\u003c\/td\u003e\n\u003ctd\u003eINDs\/FDA talks\u003c\/td\u003e\n\u003ctd\u003e5+\/20+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003ePassage Bio BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe Passage Bio BCG Matrix you're previewing is the exact final document you'll receive after purchase—no watermarks, no placeholders, just the fully formatted, analysis-ready report tailored for strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56748628214137,"sku":"passagebio-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/passagebio-bcg-matrix.png?v=1772210019","url":"https:\/\/growthsharematrix.com\/products\/passagebio-bcg-matrix","provider":"Growth Share Matrix","version":"1.0","type":"link"}